Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk tees up phase 3 trial for once-weekly insulin | Fierce Biotech
Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
